{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05279001",
            "orgStudyIdInfo": {
                "id": "ZGJAKUS001"
            },
            "organization": {
                "fullName": "Suzhou Zelgen Biopharmaceuticals Co.,Ltd",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Safety and Tolerability Study of Jaktinib",
            "officialTitle": "A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK Inhibitor",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-safety-and-tolerability-study-of-jaktinib"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-02",
            "studyFirstSubmitQcDate": "2022-03-03",
            "studyFirstPostDateStruct": {
                "date": "2022-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Suzhou Zelgen Biopharmaceuticals Co.,Ltd",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.",
            "detailedDescription": "This study is a Phase 1, single-arm, open-label, dose escalation trial, to evaluate the safety and tolerability of Jaktinib in patients with PMF or Post-PV/ET MF and who are relapsed/refractory to a marketed JAK inhibitor"
        },
        "conditionsModule": {
            "conditions": [
                "Myelofibrosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 26,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Jaktinib",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Jaktinib Hydrochloride Tablet"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Jaktinib Hydrochloride Tablet",
                    "description": "Orally administered, twice a day",
                    "armGroupLabels": [
                        "Jaktinib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety of jaktinib hydrochloride tablets",
                    "description": "Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment",
                    "timeFrame": "At least 24 weeks, up to approximately 1 year for follow-up"
                },
                {
                    "measure": "Dose-limiting toxicities (DLTs) of jaktinib hydrochloride tablets",
                    "description": "Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment",
                    "timeFrame": "28 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Efficacy of jaktinib hydrochloride tablets",
                    "description": "reduction of spleen volume of \u226535%",
                    "timeFrame": "at least 24 weeks, up to approximately 1 year"
                },
                {
                    "measure": "Efficacy of jaktinib hydrochloride tablets",
                    "description": "reduction of total symptoms score (TSS) of \u226550%",
                    "timeFrame": "at least 24 weeks, up to approximately 1 year"
                },
                {
                    "measure": "Pharmacokinetic characteristics of jaktinib hydrochloride tablets",
                    "description": "Peak Plasma Concentration (Cmax)",
                    "timeFrame": "7 days"
                },
                {
                    "measure": "Pharmacokinetic characteristics of jaktinib hydrochloride tablets",
                    "description": "Time to maximum concentration (Tmax)",
                    "timeFrame": "7 days"
                },
                {
                    "measure": "Pharmacokinetic characteristics of jaktinib hydrochloride tablets",
                    "description": "Half-life (T1/2)",
                    "timeFrame": "7 days"
                },
                {
                    "measure": "Pharmacokinetic characteristics of jaktinib hydrochloride tablets",
                    "description": "Clearance (CL/F)",
                    "timeFrame": "7 days"
                },
                {
                    "measure": "Pharmacokinetic characteristics of jaktinib hydrochloride tablets",
                    "description": "Area under Curve (AUCinf)",
                    "timeFrame": "7 days"
                },
                {
                    "measure": "Pharmacokinetic characteristics of jaktinib hydrochloride tablets",
                    "description": "Volume of distribution",
                    "timeFrame": "7 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).\n* Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.\n* At least 18 years of age.\n* ECOG PS 0, 1, or 2.\n* Expected life expectancy is greater than 24 weeks.\n\nExclusion Criteria:\n\n* Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.\n* Major surgery or radiation therapy within 28 days prior to initiation of study drug.\n* With suspected allergies to jaktinib or its excipient.\n* Another clinical trial of a new drug or medical instrument within 3 months before screening.\n* Females who are pregnant, currently breastfeeding, planning to become pregnant.\n* Unable to adopt effective contraceptive methods during the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jason Wu, M.D",
                    "role": "CONTACT",
                    "phone": "+86-21-58942758",
                    "email": "wujs@zelgen.com"
                }
            ],
            "locations": [
                {
                    "facility": "Site 01",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Ohio",
                    "zip": "44718",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jason Wu",
                            "role": "CONTACT",
                            "email": "wujs@zelgen.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.79895,
                        "lon": -81.37845
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000055728",
                    "term": "Primary Myelofibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13972",
                    "name": "Polycythemia Vera",
                    "relevance": "LOW"
                },
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13971",
                    "name": "Polycythemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M16681",
                    "name": "Thrombocytosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M16679",
                    "name": "Thrombocythemia, Essential",
                    "relevance": "LOW"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4614",
                    "name": "Polycythemia Vera",
                    "relevance": "LOW"
                },
                {
                    "id": "T2144",
                    "name": "Essential Thrombocythemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M1474",
                    "name": "Janus Kinase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}